Generated: April 28, 2017
|Title:||Venlafaxine for the treatment of generalized anxiety disorder|
|Abstract:||This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, aakyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.|
|Inventor(s):||Rudolph; Richard L. (Berwyn, PA), Upton; G. Virginia (Radnor, PA)|
|Assignee:||American Home Products Corporation (Madison, NJ)|
1. A method of treating generalized anxiety disorder in a mammal, the method comprising administering to the mammal an effective amount of
1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.
3. The method of claim 1 wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.